Current challenges in the treatment of cardiac fibrosis: Recent insights into the sex‐specific differences of glucose‐lowering therapies on the diabetic heart: IUPHAR Review 33-Reference-Cited by-同舟云学术

Current challenges in the treatment of cardiac fibrosis: Recent insights into the sex‐specific differences of glucose‐lowering therapies on the diabetic heart: IUPHAR Review 33

Published:2022-03-10 Issue: Volume: Page:
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:British J Pharmacology

Author:

Sharma Abhipree¹^ORCID,De Blasio Miles¹²^ORCID,Ritchie Rebecca¹²³^ORCID

Affiliation:

1. Heart Failure Pharmacology, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences (MIPS) Monash University Parkville Victoria Australia

2. Department of Pharmacology Monash University Clayton Victoria Australia

3. Department of Medicine Monash University Clayton Victoria Australia

Funder

National Health and Medical Research Council

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bph.15820

Reference148 articles.

1. Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3β and p38α/MAPK in a rat model of diabetic cardiomyopathy